Abbott Labs Testosterone Suits Consolidated in Chicago
This article is for subscribers only.
Abbott Laboratories and AbbVie Inc. will face lawsuits combined in one Chicago court over claims they hid the risks of using the testosterone-replacement drug AndroGel.
Abbott and AbbVie, a company Abbott spun off last year, are both based in the Chicago area and “a significant number” of AndroGel suits already are pending before U.S. District Judge Matthew Kennelly there, a panel of judges said yesterday it its decision to consolidate the cases. Kennelly will oversee pretrial information exchanges as part of the consolidation.